Dr. Pau is a Clinical Staff Scientist at the National Institute of Allergy and Infectious Disease, NIH, USA. Prior to joining the NIH, Dr. Pau was a Clinical Associate Professor at the University of Illinois College of Pharmacy. Dr. Pau specializes in infectious diseases, with clinical and research focus in HIV treatment failure and drug resistance. Her other area of focus is treatment guidelines development.
Dr. Pau has been the Executive Secretary of the US HHS Antiretroviral Guidelines Panel since 2004. She is a co-leader of the Opportunistic Infection Guidelines Panel, and the leader of the Pharmacology Team for the guidelines until 2022.
In March 2020, Dr. Pau was appointed as the Executive Secretary of the NIH COVID-19 Treatment Guidelines Panel. Dr. Pau oversees all aspects of the guideline development process, coordinating the work of over 50 Panel members from different US government agencies, researchers, academicians, and clinicians with expertise in infectious diseases, critical care, and clinical trial designs. In January 2022, Dr. Pau initiated a collaboration with the University of Liverpool and University of Toronto teams to address the challenges in providing guidance for clinicians on the use of a 5-day course of ritonavir-boosted nirmatrelvir (Paxlovid) with concomitant medications.
